Back to search results

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v8 · Stage IV Hepatocellular Carcinoma AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

    Contact: Study coordinator (Site Public Contact) · ucstudy@uci.edu · 877-827-8839
    Contact: Principal Investigator (April Choi)

  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

    Contact: Study coordinator (Site Public Contact) · ucstudy@uci.edu · 877-827-8839
    Contact: Principal Investigator (April Choi)

  • Oregon Health and Science University, Portland, Oregon, United States

    Contact: Study coordinator (Site Public Contact) · trials@ohsu.edu · 503-494-1080
    Contact: Principal Investigator (Emerson Y. Chen)

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · 412-647-8073
    Contact: Principal Investigator (Anwaar Saeed)
Study leads

  • Anwaar Saeed

    Principal Investigator

    UPMC Hillman Cancer Center LAO

View source on ClinicalTrials.gov(opens in a new tab)